NASDAQ · INDV
Indivior Pharmaceuticals, Inc.
$40.53 +$0.02 (+0.04%) 1D After hoursKey Metrics
$4.79B
Market cap
19.01×
P/E · TTM
$1.29B
Revenue · TTM
$252.00M
Net income
EPS · TTM
$2.02
Dividend yield
—
Free cash flow
−$192.00M
Beta · 1Y
0.44
EBITDA · TTM
$302.00M
Gross margin
81.4%
Snapshot
Market cap$4.79B
Enterprise value$5.07B
Shares outstanding118.2M
52-wk range$16.99 – $42.81
Avg volume · 20D1.2M
Net cash
−$284.00M
Book value / share$-1.15
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Indivior Pharmaceuticals, Inc.
IPO dateDec 24, 2014
Employees838
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E19.01
P/S3.71
P/FCF—
EV/EBITDA16.80
EV/Sales3.93
Graham №—
Profitability
Gross
81.4%
Operating
22.9%
Net
19.5%
FCF
-14.9%
ROE / ROIC
-102.4% · 150.3%
Financial Health
Current ratio0.86
Quick ratio0.66
Debt / equity-3.38
Debt / EBITDA
1.61
Net cash
−$284.00M
Working capital−$112.00M
Cash Flow · TTM
Operating CF
−$111.00M
Capex
−$81.00M
Free cash flow
−$192.00M
Buybacks
$126.00M
Dividends paid
—
Shareholder yield
2.6%
Piotroski F-Score
3 / 9
Weak fundamentals · 3 of 9 signals passing
Altman Z-Score
3.6
Safe zone (> 2.99) · bankruptcy risk negligible
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings